动物造模,心脏肥大 z-bio 2021-04-29 245

　　Objective: To find important biomarkers through serum metabolomics to study the cause of cardiac hypertrophy in rats.

　　Method: The rat cardiac hypertrophy model was established by intraperitoneal injection of 30 mg/(kg·D) isoproterenol for 30 consecutive days. The heart mass index is used to evaluate the rat model of cardiac hypertrophy. Ultra performance liquid chromatography uses quadrupole time-of-flight tandem mass spectrometry to detect endogenous metabolites in rat serum, and uses MPP software and human metabolome database (HMDB) to analyze metabolite differences, which is used to determine biomarkers . For analysis of metabolic pathways.

　　Result: Intraperitoneal injection of isoproterenol can cause cardiac hypertrophy in rats. There are significant differences in serum metabolites between the cardiac hypertrophy model group and the normal group, and a total of 10 potential biomarkers have been identified. Compared with the normal group, the myocardial hypertrophy model group had significantly down-regulated sphingosine 1-phosphate and dihomo-γ-linolenic acid, D-fructose-1,6-diphosphate, deoxyadenosine and N-acetylmethionine Acid, phytosphingosine, allantoin, 3-keto-β-D-galactose, octane and glycerol were all significantly up-regulated.

　　Conclusion: Cardiac hypertrophy caused by isoprene includes metabolic pathways, such as sphingolipid metabolism, glycerolipid metabolism, galactose metabolism, unsaturated fatty acid biosynthesis and purine metabolism. This study provides a reference for revealing the changes in circulating blood metabolism in cardiac hypertrophy induced by isoproterenol.